Nattopharma has signed an exclusive distribution agreement with Glanbia Nutritionals which will see NattoPharma's new ingredient, MenaQ7 PURE, a nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7) distributed throughout the United States and Canada by Glanbia Nutritionals.
"MenaQ7 PURE is the newest offering in Glanbia Nutritionals' arsenal of unique, proprietary, branded, clinically substantiated, and validated ingredients," said Hogne Vik, CEO of NattoPharma. "The market for vitamin K2 as MK-7 is clearly expanding as the scientific evidence of its ability to promote bone and cardiovascular health continues to accumulate. As vitamin K2 awareness has been rapidly growing, NattoPharma has been fielding an influx of inquiries. Glanbia Nutritionals' broad and deep customer base will benefit from this vital new offering, which will further enhance NattoPharma’s U.S. presence.”
“This is a breakthrough for the work we have been consistently advancing in the United States, as we have said that we have been in contact with some large U.S. companies. Building strong partnerships is a long process, but one that is extremely gratifying when it comes to fruition,” said Froce Marc Bohan, chairman of the board at NattoPharma. "Glanbia's expertise and network is a fantastic start to help create a healthier, more robust population."
NattoPharma's MenaQ7 PURE is produced in a European pharmaceutical manufacturing facility and is said to be fully validated by numerous human clinical studies, as well as in-vivo and in-vitro research.
